Supernus Pharmaceuticals Inc (SUPN) Shares Sold by Oppenheimer Asset Management Inc.

Oppenheimer Asset Management Inc. cut its stake in Supernus Pharmaceuticals Inc (NASDAQ:SUPN) by 11.0% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 13,562 shares of the specialty pharmaceutical company’s stock after selling 1,679 shares during the period. Oppenheimer Asset Management Inc.’s holdings in Supernus Pharmaceuticals were worth $812,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Everence Capital Management Inc. acquired a new position in Supernus Pharmaceuticals in the 2nd quarter worth $205,000. Cim LLC acquired a new position in Supernus Pharmaceuticals in the 2nd quarter worth $207,000. Diversified Trust Co acquired a new position in Supernus Pharmaceuticals in the 1st quarter worth $211,000. Wesbanco Bank Inc. acquired a new position in Supernus Pharmaceuticals in the 1st quarter worth $229,000. Finally, Mount Yale Investment Advisors LLC acquired a new position in Supernus Pharmaceuticals in the 1st quarter worth $238,000. 97.42% of the stock is owned by hedge funds and other institutional investors.

Shares of NASDAQ:SUPN opened at $45.80 on Friday. The company has a current ratio of 2.74, a quick ratio of 2.54 and a debt-to-equity ratio of 0.82. Supernus Pharmaceuticals Inc has a one year low of $33.30 and a one year high of $61.25. The stock has a market cap of $2.37 billion, a price-to-earnings ratio of 36.35 and a beta of 0.83.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings results on Tuesday, August 7th. The specialty pharmaceutical company reported $0.57 EPS for the quarter, topping the consensus estimate of $0.43 by $0.14. Supernus Pharmaceuticals had a net margin of 24.17% and a return on equity of 30.57%. The firm had revenue of $99.54 million for the quarter, compared to analysts’ expectations of $101.01 million. equities analysts forecast that Supernus Pharmaceuticals Inc will post 1.98 EPS for the current fiscal year.

A number of equities analysts recently weighed in on SUPN shares. ValuEngine lowered shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, August 13th. BidaskClub raised shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, May 16th. Piper Jaffray Companies set a $47.00 price target on shares of Supernus Pharmaceuticals and gave the stock a “hold” rating in a research report on Monday, July 2nd. Zacks Investment Research cut shares of Supernus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, August 1st. Finally, Stifel Nicolaus boosted their price target on shares of Supernus Pharmaceuticals from $50.00 to $60.00 and gave the stock a “buy” rating in a research report on Friday, May 25th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and nine have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $54.09.

In other news, VP Stefan K.F. Schwabe sold 60,000 shares of the company’s stock in a transaction dated Monday, June 18th. The shares were sold at an average price of $54.39, for a total value of $3,263,400.00. Following the sale, the vice president now directly owns 21,967 shares of the company’s stock, valued at approximately $1,194,785.13. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO Gregory S. Patrick sold 35,000 shares of the company’s stock in a transaction dated Monday, July 2nd. The shares were sold at an average price of $56.63, for a total transaction of $1,982,050.00. Following the completion of the sale, the chief financial officer now directly owns 75,975 shares in the company, valued at $4,302,464.25. The disclosure for this sale can be found here. Insiders have sold a total of 110,000 shares of company stock worth $6,144,826 over the last three months. Insiders own 6.20% of the company’s stock.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy.

Further Reading: Outstanding Shares and The Effect on Share Price

Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals Inc (NASDAQ:SUPN).

Institutional Ownership by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply